Tarsus closes public offering of 3.23M shares; net proceeds $134.8M

Tarsus Pharmaceuticals, Inc.

Underwriters exercised full over-allotment; total shares sold: 3,230,336 (incl. 421,348 additional shares).
Shares sold to underwriters at $41.83 each; public offering price $44.50.
Net proceeds of ~$134.8M after underwriting discounts and estimated offering expenses.
Offering closed on March 14, 2025; use of proceeds not specified but typical for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.